✦ LIBER ✦

Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene

✍ Scribed by Mika Wallén; Eija Tomás; Tapio Visakorpi; Kaija Holli; Johanna Mäenpää

Publisher: Springer
Year: 2004
Tongue: English
Weight: 193 KB
Volume: 55
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-004-0923-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Femoral fractures in postmenopausal brea

Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen

✍ Bent Kristensen; Bent Ejlertsen; Henning T. Mouridsen; Knud West Andersen; Jes B 📂 Article 📅 1996 🏛 Springer US 🌐 English ⚖ 486 KB

Femoral fractures in postmenopausal brea

Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxieen

✍ B. Kristensen; B. Ejlertsen; H. T. Mouridsen; K. W. Andersen; J. B. Lauritzen 📂 Article 📅 1996 🏛 Springer-Verlag 🌐 English ⚖ 131 KB

Genetic polymorphisms of CYP2D6*10 and C

Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

✍ Matthew Goetz; Vera Suman 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 1 views

The study by Okishiro et al 1 concludes that the cytochrome P450 (CYP) genotype CYP2D6\*10/\*10 is unlikely to have a clinically significant impact on prognosis in women with breast cancer who receive adjuvant tamoxifen. However, several aspects of the study by Okishiro et al call their conclusions

Genetic polymorphisms of CYP2D6*10 and C

Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

✍ Masatsugu Okishiro; Tetsuya Taguchi; Seung Jin Kim; Kenzo Shimazu; Yasuhiro Tama 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 469 KB 👁 1 views

Cognitive function in postmenopausal bre

Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial

✍ Kelly-Anne Phillips; Julie Aldridge; Karin Ribi; Zhuoxin Sun; Alastair Thompson; 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 241 KB

Reply to Genetic polymorphisms of CYP2D6

Reply to Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

✍ Shinzaburo Noguchi; Masatsugu Okishiro 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB 👁 1 views